HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Immune attacks are key issues for cell transplantation. To assess the safety and the immune reactions after iPS cells-derived retinal pigment epithelium (iPS-RPE) transplantation, we transplanted HLA homozygote iPS-RPE cells established at an iPS bank in HLA-matched patients with exudative age-related macular degeneration. In addition, local steroids without immunosuppressive medications were administered. We monitored immune rejections by routine ocular examinations as well as by lymphocytes-graft cells immune reaction (LGIR) tests using graft RPE and the patient’s blood cells. In all five of the cases that underwent iPS-RPE transplantation, the presence of graft cells was indicated by clumps or an area of increased pigmentation at 6 months, which became stable with no further abnormal growth in the graft during the 1-year observation period. Adverse events observed included corneal erosion, epiretinal membrane, retinal edema due to epiretinal membrane, elevated intraocular pressure, endophthalmitis, and mild immune rejection in the eye. In the one case exhibiting positive LGIR tests along with a slight fluid recurrence, we administrated local steroid therapy that subsequently resolved the suspected immune attacks. Although the cell delivery strategy must be further optimized, the present results suggest that it is possible to achieve stable survival and safety of iPS-RPE cell transplantation for a year.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This was further confirmed in a clinical trial study with five recruited HLA-matched patients who received HLA-matched RPE cells [97]. In all five cases, survival of transplanted cells was observed one year later, without the need for systemic immune suppression.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A more efficient method to generate integration-free human iPS cells
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K.-I., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1591 · Cited by 2,061 · cited 8×
“Therefore, the present clinical study was designed to use allografts of iPS-RPE cells from an HLA homozygous donor prepared at the Center for iPS Cell Research and Application (CiRA) iPS bank [21] for wet AMD patients with the same HLA haplotype identity.”
BackgroundMethodInfluentialSelf-citationPrevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845
Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608368 · Cited by 1,509 · cited 4×
“The marker and function for the iPS cells-derived RPE cells were similar to that observed with our previous RPE cells [20].”
BackgroundMethodResultInfluentialSelf-citationImmunogenicity of induced pluripotent stem cells
Zhao, T., Zhang, Z.-N., Rong, Z., & Xu, Y. (2011) · Nature · doi:10.1038/nature10135 · Cited by 1,444 · cited 1×
“Moreover, we have as of yet no definitive answer as to how the immune rejection in the eye occurred in only one case, even though several events such as iPS-associated immune attacks [32], minor antigens, natural killer cell attacks (e.”
BackgroundEmbryonic stem cell trials for macular degeneration: a preliminary report
Schwartz, S. D., Hubschman, J.-P., Heilwell, G., Franco-Cardenas, V., Pan, C. K., Ostrick, R. M., Mickunas, E., Gay, R., Klimanskaya, I., & Lanza, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60028-2 · Cited by 1,409 · cited 1×
“However, it was also found that some of these patients had adverse events due to systemic immunosuppressive medications [28], which can be a physical burden in elderly patients.”
BackgroundSchwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327
Prevalence of age-related maculopathy in Australia
Mitchell, P., Smith, W., Attebo, K., & Wang, J. J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30846-9 · Cited by 1,062
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023 · cited 1×
“However, anti-VEGF treatments often require continual injections for years and thus, it can be difficult to retain visual acuity in real-world clinics [8].”
BackgroundThe Prevalence of Age-related Maculopathy in the Rotterdam Study
Vingerling, J. R., Dielemans, I., Hofman, A., Grobbee, D. E., Hijmering, M., Kramer, C. F. L., & de Jong, P. T. V. M. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)31034-2 · Cited by 815
Ocular immune privilege: therapeutic opportunities from an experiment of nature
Streilein, J. W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1224 · Cited by 807 · cited 2×
“Moreover, the eye is also known to be a unique organ with a unique environment that has both anti-inflammatory and immunosuppressive mechanisms [16,17].”
Background
Cited by
Items 101–200 of 200
Dong, C., Zou, D., Duan, H., Hu, X., Zhou, Q., Shi, W., & Li, Z. (2023) · Eye and Vision · doi:10.1186/s40662-023-00351-4 · Cited by 8
Hereditary Optic Neuropathies: Induced Pluripotent Stem Cell-Based 2D/3D Approaches
García‐López, M., Arenas, J., & Gallardo, M. E. (2021) · Genes · doi:10.3390/genes12010112 · Cited by 9
“HLA-matched allogeneic iPS-RPE cells were grafted to AMD patients, and, although the cell delivery strategy must be further optimized, one year later, the RPE grafts survived and were safe [144].”
BackgroundSatake, T., Komura, S., Aoki, H., Hirakawa, A., Imai, Y., & Akiyama, H. (2022) · BMC Molecular and Cell Biology · doi:10.1186/s12860-022-00431-8 · Cited by 8
Integrating living biomaterials into neuroelectronic systems
Hong, M., Ye, Y., Kim, J., Kim, J., Rah, J., & Tchoe, Y. (2026) · Biomedical Engineering Letters · doi:10.1007/s13534-026-00557-0 · Cited by 8
“Related cell-therapy strategies are already being advanced clinically for tissue repair and neurodegenerative indications [164–169 ], underscoring both the motivation for patient-matched approaches and the stringent safety expectations for stem cell–derived products [170–173].”
Ocular stem cells: a narrative review of current clinical trials
Sotiropulos, K., Almaliotis, D. D., Ploumidou, K., & Karampatakis, V. E. (2022) · International Journal of Ophthalmology · doi:10.18240/ijo.2022.09.17 · Cited by 7
Latest trends & strategies in ocular drug delivery
Kulkarni, N. S., Josowitz, A. D., James, R., Liu, Y., Rayaprolu, B. M., Sagdullaev, B. T., Bhalla, A. S., & Shameem, M. (2025) · Methods · doi:10.1016/j.ymeth.2025.02.003 · Cited by 8
Emerging biological therapies for the treatment of age-related macular degeneration
Asahi, M., Avaylon, J., Wallsh, J. O., & Gallemore, R. P. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1931120 · Cited by 8
“No eyes were reported to have signs of graft rejection during follow-up[113].”
BackgroundUtilization of Stem Cells in Medicine: A Narrative Review
Mendi, B. İ., Hirani, R., Sayegh, A., Hassan, M., Fleshner, L., Farabi, B., Atak, M. F., & Safai, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199659 · Cited by 9
“In all cases that underwent iPS-RPE transplantation, the presence of graft cells was indicated by areas of increased pigmentation at 6 months, which became stable during the 1 year observation period [177].”
Lv, Y. X., Li, Q. Y., Duan, P., Zhang, M. F., Liu, B., Li, S., Zhao, T. T., Wang, H., Liu, Y., & Yin, Z. Q. (2025) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102424 · Cited by 9
Pigmentation level of human iPSC-derived RPE does not indicate a specific gene expression profile
Nakai, Y., Jin, J., Ogawa, T., Sakai, N., Maeda, A., Hironaka, K., Fukuda, M., Danno, H., Tanaka, Y., Hori, S., et al. (2024) · eLife · doi:10.7554/elife.92510 · Cited by 7
“…highly pigmented when transplanted ( Sengupta et al., 2009 ), as well as our iPSC-RPE cells that are not pigmented when prepared but actually become heavily pigmented after engrafted ( Mandai et al., 2017 ; Sugita et al., 2020 ), suggest the significance of environmental niche for melanogenesis.”
BackgroundSelf-citationSakai, D., Maeda, T., Maeda, A., Yamamoto, M., Yokota, S., Hirami, Y., Nakamura, M., Takahashi, M., Mandai, M., & Kurimoto, Y. (2024) · Retina · doi:10.1097/iae.0000000000004114 · Cited by 6
Self-citationMizutani, M., Nakajima, K., & Kino‐oka, M. (2022) · Regenerative Therapy · doi:10.1016/j.reth.2022.02.004 · Cited by 6
Tissue engineering of outer blood retina barrier for therapeutic development
Hampton, C., Bharti, K., & Song, M. J. (2024) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2024.100538 · Cited by 10
The hope, hype and obstacles surrounding cell therapy
Tręda, C., Włodarczyk, A., & Rieske, P. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18359 · Cited by 5
“In two completed clinical trials, 16,17 a copy number change was detected in the iPSC-derived retinal pigment epithelium in one case, but it did not lead to the formation of a teratoma.”
BackgroundWu, K. Y., Osman, R. M., Esomchukwu, O., Marchand, M., Nguyen, B. H., & Tran, S. D. (2025) · Advances in experimental medicine and biology · doi:10.1007/5584_2025_854 · Cited by 5
Zhang, H., del Barrio, J. L. A., Miguel, M. P. D., & Alió, J. L. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110631 · Cited by 5
Beaver, D., & Limnios, I. J. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1130086 · Cited by 5
“…HLA match for the patient, however, the current technological limitations, including the time and effort required to generate and validate patient-speci fi c hIPSC clones and the need for genetic modi fi cation of disease alleles before differentiation, make this approach impractical (84, 243).”
BackgroundProgress of Induced Pluripotent Stem Cell-Derived Renal Organoids in Clinical Application
Ning, N., Liu, Z., Li, X., Liu, Y., & Song, W. (2024) · Kidney Diseases · doi:10.1159/000541919 · Cited by 7
“Both autologous iPSC-derived retinal pigment epithelial cells [63] and human leukocyte antigen (HLA)- matched allogeneic iPSCs-derived retinal pigment epithelium [64] have been reported to successfully transplant into age-related macular degeneration and remain intact and safe in 1 year.”
Japan to Global Eye Genetics Consortium: Extending Research Collaboration for Inherited Eye Diseases
Iwata, T. (2022) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000535 · Cited by 5
Les organoïdes hépatiques: Quels sont les enjeux ?
Luce, E., Messina, A., Caillaud, A., Si‐Tayeb, K., Cariou, B., Bur, E., Dubart‐Kupperschmitt, A., & Duclos‐Vallée, J. (2021) · médecine/sciences · doi:10.1051/medsci/2021119 · Cited by 7
Motozawa, N., Miura, T., Ochiai, K., Yamamoto, M., Horinouchi, T., Tsuzuki, T., Kanda, G. N., Ozawa, Y., Tsujikawa, A., Takahashi, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05006-3 · Cited by 6
Self-citationMacrophages in age-related macular degeneration: a narrative review
Khademi, S., Yu, Z., Zhou, T., Song, B., & Xu, Z. (2024) · Aging advances. · doi:10.4103/agingadv.agingadv-d-24-00007 · Cited by 5
Ozaki, A., Sugita, S., Ishida, M., Nishida, M., Iseki, K., Sakai, N., Hayashi, N., Shiina, T., Yokota, S., Ito, S.-I., et al. (2025) · Investigative Ophthalmology and Visual Science · doi:10.1167/iovs.66.6.53 · Cited by 4
“5 8 However, such case-dependent cell production remains costly and time-consuming.”
Self-citationApplications of Modern Cell Therapies: The Latest Data in Ophthalmology
Iliadis, I., Печникова, Н. А., Poimenidou, M., Almaliotis, D. D., Tsinopoulos, I., Yaremenko, T. V., & Yaremenko, A. V. (2025) · Life · doi:10.3390/life15101610 · Cited by 9
Miyamoto, D., Matsuguma, K., Nagai, K., Miyoshi, T., Hara, T., Matsushima, H., Soyama, A., Ochiya, T., Miyazaki, Y., & Eguchi, S. (2024) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.12046 · Cited by 5
Induction of γδT cells from HSC‐enriched BMCs co‐cultured with iPSC‐derived thymic epithelial cells
Hosaka, N., Kanda, S., Shimono, T., & Nishiyama, T. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16993 · Cited by 4
Kuwata, F., Ohnishi, H., Yamamoto, N., Takezawa, T., Yamashita, M., Okuyama, H., Hayashi, Y., Yoshimatsu, M., Kitada, Y., Tada, T., et al. (2021) · Tissue Engineering Part A · doi:10.1089/ten.tea.2021.0071 · Cited by 4
“11 AECs derived from mouse iPSCs 12 or human induced pluripotent stem cells (hiPSCs) 13 were transplanted with artificial trachea into tracheal defects in nude rats to promote epitheli-alization of the defects.”
Multimodal Imaging in Stem Cell Therapy for Retinal Disease
Zheng, M., & Paulus, Y. M. (2025) · Photonics · doi:10.3390/photonics12050413 · Cited by 5
Ching, J., Arai, M., Oba, M., Miyazato, M., Kobayashi, Y., Tanaka, S., Kitahata, S., Inoue, T., Maruyama-Inoue, M., & Kadonosono, K. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-06960-0 · Cited by 3
“Finally, induced pluripotent stem cell derived RPE cells have been delivered as cell suspensions with such cannulae but there is still room for improvements given that cell reflux through the retinal wound is thought to cause epiretinal membranes [ 35 ].”
Zhang, H., Liu, Z., Wu, L., Yuan, J., Zhang, X., Zhang, X., Li, Y., Liu, F., & Jin, Z. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.15.1 · Cited by 4
“14 In this study, we employed stem cell reprogramming technology to develop a patient-specific RPE model to investigate changes in RPE-derived EV secretion in MERTK -associated retinal degeneration.”
Wei, Q.-S., Xing, Q.-Y., Ma, Y.-H., Zhang, K.-J., Ma, W., Zhang, M., Shi, H.-J., Peng, L., WANG, J.-H., Hu, Q.-X., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.177575 · Cited by 4
Sung, T., Pan, Z.-X., Wang, T., Lin, H.-Y., Chang, C.-L., Hung, L.-C., Kumar, S. S., Renuka, R. R., Chou, S., Chiou, S., et al. (2025) · Regenerative Biomaterials · doi:10.1093/rb/rbaf003 · Cited by 2
Ciszewski, P., Drelichowska, A., Pikor, D., Wiśniewska, E., & Azierski, M. (2025) · Romanian Journal of Ophthalmology · doi:10.22336/rjo.2025.03 · Cited by 6
“Clinical studies indicate that iPSC-RPE transplantation is relatively safe, with minimal rejection controlled by topical steroids, and the grafts remain stable for at least one year, despite minor complications such as mild immune reactions or epiretinal membrane formation [ 19,20 ].”
Pluripotent stem cell-derived cardiomyocyte transplantation: marching from bench to bedside
Yi, H., Liu, J., Wang, W., Li, H., Kong, W., Li, X., Zhang, W., Pahlavan, S., Tang, Y., Wang, X., et al. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2801-x · Cited by 2
Marmorstein, A. D., Scruggs, B. A., Knudsen, T., Hill, M., Kopp, F., Trncic, E., Korda, D., Atherton, E., Berger, A., Finnemann, S. C., et al. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1739620 · Cited by 2
Ma, J., Zhu, L., Duan, P., Ding, T., Cheng, Z., Li, B., Wang, Q., Ma, X., Deng, Y., Lamba, D. A., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.05.006 · Cited by 2
Induced pluripotent stem cells from discovery to translation
Lee, J., Herron, T. J., Studer, L., Mummery, C. L., & Wu, J. C. (2026) · Nature Medicine · doi:10.1038/s41591-026-04584-3 · Cited by 3
A rabbit model for outer retinal atrophy caused by surgical RPE removal
Al-Nawaiseh, S., Krötz, C., Rickmann, A., Strack, C., Germann, A., von Briesen, H., Szurman, P., Schulz, A., & Stanzel, B. V. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06014-3 · Cited by 2
Induced pluripotent stem-cell-derived corneal grafts and organoids
Pulimamidi, V. K., Maddileti, S., & Mariappan, I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823809-7.00005-0 · Cited by 2
Induced pluripotent stem cells–derived hematopoietic progenitors for cellular immunotherapies
Slukvin, I. I., D'Souza, S. S., & Kumar, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85545-7.00007-7 · Cited by 2
An update on clinical applications of iPSCs from a genomic point of view
Yoshihara, M., & Murakawa, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99892-5.00001-3 · Cited by 2
Ando, M., Kato, A., Kimura, M., Ogura, S., Kuwayama, S., Kominami, A., Kuwayama, S., Obayashi, T., Ando, R., Monoe, T., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082417 · Cited by 2
“…or intravitreous injection of AAV2-sFLT01 [14], and transplantation of retinal pigment epithelial (RPE) cells derived from induced pluripotent stem cells (iPSCs) [15] or HLA-matched allogeneic iPSC-derived retinal cells [16], have received considerable attention as potential treatments for nvAMD.”
BackgroundBhat, M. A., & Goyal, S. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10927-3 · Cited by 1
“This reduces the risk of immune rejection, making iPSCs a highly promising tool for regenerative medicine [ 105 , 106 ].”
Investigating Microinvasive Intra‐Ocular Biopsy
Ching, J., Kitahata, S., Ichikawa, H., & Kadonosono, K. (2025) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14591 · Cited by 1
Visual Neurorestoration: An Expert Review of Current Strategies for Restoring Vision in Humans
Cavaleri, J., Lin, M. P., Wu, K., Gilbert, Z. D., Huang, C. Y., Lo, Y. T., Garimella, V., Dallas, J., Briggs, R. G., Borja, A. J., et al. (2025) · Brain Sciences · doi:10.3390/brainsci15111170 · Cited by 1
Advances in the treatment of blinding retinal diseases
Zhao, L., Jin, S., Xu, W., Zhang, M., & Liu, X. (2025) · International Ophthalmology · doi:10.1007/s10792-025-03876-w · Cited by 1
“In contrast, allogeneic approaches utilizing human leukocyte antigen (HLA)-matched iPSCs offer enhanced cost-effectiveness and scalability through standardized cell banking [12–14].”
Deep immune-phenotyping of HLA-homozygous iPS-cardiomyocytes by spectral flow cytometry
Maeding, N., Kundully, D. S., Steinhuber, A., Kriedemann, N., Hernandez-Bautista, C. A., Martins, S., Hochmann, S., Martin, W., Mayr, W. R., Jungbauer, C., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1736994 · Cited by 1
“HLA-homozygous hiPSC-derived retinal pigment epithelial cells have been successfully transplanted in allogeneic settings without additional immunosuppression (43).”
CRISPR and Beyond: Genome-Editing Strategies in Retinal Stem Cell Research
Woronkowicz, M., Thomas, M. N., Saram, S. J., Carr, A. F., Fernández, A. A.-C., Butt, Z., Skopiński, P., & Ramsden, C. M. (2026) · Cells · doi:10.3390/cells15060489 · Cited by 2
“In ad-https://doi.org/10.3390/cells15060489 dition, autologous cells may harbour disease causing mutations, particularly in patients with pre-existing genetic conditions, making allogeneic grafts a potentially more viable option [51,52].”
InfluentialBhargava, M., Mehta, K. N., Parikh, B. H., Liu, Z., & Su, X. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-04971-0 · Cited by 2
“However, ERM, macular edema, and signs of rejection were observed despite simultaneous administration of anti-VEGF and local immunosuppression [26].”
Cellular Products with Anti-Inflammatory Properties for the Treatment of Cartilage Lesions
Александровна, Г. П., Ruchko, E. S., Bogomazova, A. N., & Валерьевич, Е. А. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104316 · Cited by 2
“…including myocardial infarction [180–182], spinal cord injury [183], Parkinson’s disease [184,185], and age-related macular degeneration [186–190]. iPSCs are also being leveraged to generate immune cells (e.g., NK cells, T-lymphocytes) for cancer immunotherapy [191,192] and to address…”
Satake, T., Komura, S., Aoki, H., Hirakawa, A., Imai, Y., & Akiyama, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1400781/v1
Advanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges
Diebold, Y., & García-Posadas, L. (2021) · MDPI eBooks · doi:10.3390/books978-3-0365-2610-2
Gao, S., Mo, L., Li, M., Zou, T., & HaiWei, X. U. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0075 · Cited by 1
Satake, T., Komura, S., Aoki, H., Hirakawa, A., Imai, Y., & Akiyama, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1400781/v2
Drouin‐Ouellet, J., Li, D., Lu, Y. R., & Echegaray, C. V. (2022) · Cellular Reprogramming · doi:10.1089/cell.2022.0105
“Vision Care, Inc., has also conducted a second clinical research using HLA-matched allogeneic iPSC-RPE transplantation (five cases total) to show the possibility of allogeneic transplantation without systemic immune suppression for elder patients (Sugita et al, 2020).”
Induced Pluripotent Stem Cells: Progress toward Clinical Translation from Bench to Bedside
Fakoya, A. O. J., Omole, A. E., Satyadev, N., & Haider, K. H. (2022) · Springer eBooks · doi:10.1007/978-981-19-2655-6_40
Zhang, H., & Jin, Z. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99987-8.00008-4 · Cited by 1
Follin, B., Caluori, G., Dobrolińska, M. M., Stachura, J., Muzzamil, H., Wojakowski, W., Qayyum, A. A., & Jadczyk, T. (2023) · Springer eBooks · doi:10.1007/978-981-99-0722-9_3
Nakai, Y., Jin, J., Ogawa, T., Sakai, N., Maeda, A., Hironaka, K., Fukuda, M., Danno, H., Tanaka, Y., Hori, S., et al. (2024) · eLife · doi:10.7554/elife.92510.2.sa3
Self-citationMano, F., LoBue, S., Tailor, P. D., & Olsen, T. W. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.08.002
Bao, Y. K., Engelhard, S., & Brant, R. (2024) · Springer eBooks · doi:10.1007/978-3-031-29358-0_21-1
Yamanari, M. (2024) · Nippon Laser Igakkaishi · doi:10.2530/jslsm.jslsm-45_0049
Microneedle delivery of stem cell derived retinal pigment epithelial cellsPreprint
Ching, J., Ichikawa, H., Kitahata, S., Morrow, L. C., & Kadonosono, K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.29.651158
Biomaterials in Retinal Regeneration
Hicks, E. A., Monteiro, A., Tran, N., Sheardown, L., & Sheardown, H. D. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781839169779-00256
Tsuneyoshi, N., Hosoya, T., Takeno, Y., Saitoh, K., Murai, H., Amimoto, N., Tatsumi, R., Watanabe, S., Hasegawa, Y., Kikkawa, E. F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26741663
Dong, C., Zou, D., Duan, H., Hu, X., Zhou, Q., 史伟云, & Li, Z. (2023) · Figshare · doi:10.6084/m9.figshare.23819968
Dong, C., Zou, D., Duan, H., Hu, X., Zhou, Q., 史伟云, & Li, Z. (2023) · Figshare · doi:10.6084/m9.figshare.23819971
島谷幸宏, & Shimaya, Y. (2025) · Institutional Repositories DataBase (IRDB)
Vision Restoration in Degenerative Retinal Diseases Using Stem Cells
Viswanathan, H., Goyal, I., Rana, S., Singh, S., Singh, R., & Senjam, S. S. (2025) · Journal of the Epidemiology Foundation of India · doi:10.56450//jefi.2025.v3i1suppl.005
“(70,67) • Refinements in delivery.”
Nandakumar, S., Farjood, F., Bertucci, T. B., Lotz, S., Sai, S., Wang, Y., Kozak, J. A., Arduini, B. L., Stern, J. H., Boles, N. C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.26.708319
Arduini, B. L., Blenkinsop, T. A., Naimark, M., Borden, S. M., Charniga, C. J., Campbell, M., Rugenstein, N., Davis, R. J., Alam, N. M., Prusky, G. T., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102779
“Pluripotent stem cell (PSC) sources of RPE (PSC-RPE) are undergoing clinical investigation, 6–14 with positive early outcomes.”
Lee, Y.-C., Lai, P., Lai, C.-Y., Chang, F.-L., Wu, S.-Y., Lin, P.-Y., Chuang, C., Chou, Y.-X., Chen, Z., Wu, Y.-C., et al. (2026) · Journal of Functional Biomaterials · doi:10.3390/jfb17050236
“Clinical investigations using human embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) for RPE replacement have reported structural stabilization and modest functional outcomes in treated patients [10–15].”
Partial Fluid-Air Exchange Enhances Submacular Injection of Retinal Sheets
Baldwin, G. E., Akita, Y., Manabe, K., Kamei, T., Kuwahara, A., Bleicher, I. D., Vavvas, D. G., & Miller, J. B. (2026) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20260310-04
Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration
Musheyev, B., Kellner, R., Bouaziz, M., & Lieberman, R. M. (2026) · Advances in Ophthalmology and Optometry · doi:10.1016/j.yaoo.2026.04.001
Cell therapy for age-related macular degeneration
Shaikh, A., & Pera, M. F. (2026) · Mammalian Genome · doi:10.1007/s00335-026-10242-3
“This result strongly supports the potential for reduced immunosuppression burden through HLA matching (Sugita et al. 2020).”
Stem cell therapy in retinal disease
WANG, J., Felfeli, T., & Ballios, B. G. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00004-5
Dugiełło, B., Bujała, K., Bolek, B., Wylęgała, A., & Wylęgała, E. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01429-7
“…therapies [10], regenerative approaches including retinal pigment epithelium (RPE) cell transplantation and tissue engineering or nanotechnology-based delivery systems [11, 12], and light-based therapies or artificial intelligence-driven models for disease monitoring and personalized care [13–15].”
Mao, X., Yin, W., Xu, M., Niu, Z., Zhong, D., Ye, B., Xu, S., Gao, Y., Zhang, W., Chen, Q., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102963
3D epigenomic landscape of the human retinal pigment epithelium
Liu, X., Tang, D., Zhang, J., Li, T., Huang, J., Qu, J., Ruan, Y., Chai, H., & Chi, Z. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2526200123
“Clinical trials have shown that iPSC - RPE survives up to 2 y and delays disease pro gression, but visual improvement is limited (35, 36).”
Ungaratti, A. K. G., de Lima, A. P., Santos, J. A., de Melo, P. L., Graziani, D., da Silva, A. C. G., Silva, L. A. D., & Valadares, M. C. (2026) · Macromolecular Bioscience · doi:10.1002/mabi.70231
“The main platforms include human embryonic stem cell (hESC) derived RPE patches (da Cruz et al., 2028; [ 8 ]) and induced pluripotent stem cell (iPSC) derived RPE patches [ 9–11 ].”
The evolution of iPSC-based cell therapy across autologous and allogeneic pathways
Wang, A., Zhang, Y., Deng, H., & Gu, M. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102992
“19,57 The advantages of this model extend beyond a single clinical program.”
InfluentialHarnessing stem cells for regenerative medicine: Current applications and future prospects
Shamlou, S., Rostami, H., Hassanzadeh, A., Rajaeian, S., Goudarzi, S. T., Arab, M., Shojaeian, A., Verdi, J., & Vousooghi, N. (2026) · Journal of Clinical and Translational Research · doi:10.36922/jctr026080013
Shadforth, A. M. A., & Harkin, D. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36643-7.01012-x
Sakai, D., Hirami, Y., Takagi, S. T., Yamamoto, M., Totani, K., Yamanari, M., Fujihara, M., Sugita, S., Maeda, T., Takahashi, M., et al. (2026) · Ophthalmology Retina · doi:10.1016/j.oret.2026.09.005
Self-citationTakahashi, T., Uchiyama, R., Toyoda, E., Maehara, M., Takahashi, Y., Wasai, S., Oomura, H., Ogawa, M., Yamashita, A., Watanabe, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.25.754531
Bao, Y. K., Engelhard, S., & Fernandes, R. A. B. [. (2026) · Springer eBooks · doi:10.1007/978-3-032-23052-2_21
Schulz, A., Al-Nawaiseh, S., Wakili, P., Krötz, C., Germann, A., Farese, G., Burri, C., von Briesen, H., Claaßen, C., Schmidt, S., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.154685
van der Walle, C. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45791-3.00006-8
Shah, J. R., Pathuri, S., Sharma, R., Skottman, H., Mörö, A., Karamichos, D., Choi, A. J. S., Ong, J., Mehta, J. S., Shrivastava, A., et al. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101538
Self‐Sealing Microneedles Improve Precision and Reduce Reflux in Subretinal Cell Transplantation
Ching, J., Ichikawa, H., Motoyoshi, A., Tanaka, S., Morrow, L. C., Shirae, S., Sakai, N., Kitahata, S., Mandai, M., & Kadonosono, K. (2026) · Advanced Materials Technologies · doi:10.1002/admt.71409
Self-citationThe translational journey of human pluripotent stem cells
Thamodaran, V., Roja, K., Goswami, N., Balu, K., Kumar, V. K., & Mishra, R. K. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1978203
Metadata
- Authors
- Sugita, S., Mandai, M., Hirami, Y., Takagi, S., Maeda, T., Fujihara, M., Matsuzaki, M., Yamamoto, M., Iseki, K., Hayashi, N., Hono, A., Fujino, S., Koide, N., Sakai, N., Shibata, Y., Terada, M., Nishida, M., Dohi, H., Nomura, M., Amano, N., Sakaguchi, H., Hara, C., Maruyama, K., Daimon, T., Igeta, M., Oda, T., Shirono, U., Tozaki, M., Totani, K., Sugiyama, S., Nishida, K., Kurimoto, Y., & Takahashi, M.
- Affiliations
- RIKEN Center for Biosystems Dynamics Research (JP)
- Kobe City Medical Center General Hospital (JP)
- Toho University (JP)
- Kyoto University (JP)
- The University of Osaka (JP)
- Hyogo Medical University (JP)
- Tomey Corporation (Japan) (JP)
- Corresponding author
- Takahashi, Masayo
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-07-13
- Volume
- 9
- Issue
- 7
- Pages
- 2217
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC7408794
- OpenAlex
- W3041366976
- Cited by
- 190
- References
- 33
- Citations by year
- 2026: 27 · 2025: 28 · 2024: 34 · 2023: 24 · 2022: 36 · 2021: 36 · 2020: 5
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- AMED (JP18bm0204002, JP17bk0104002)
- KAKENHI (25293357, 18H02959, 16K21633)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- induced pluripotent stem cells, retinal pigment epithelium, cell transplantation, age-related macular degeneration, HLA matching, immune rejection, local steroid therapy, graft survival, transplant safety, epiretinal membrane, endophthalmitis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.